

# **Best Available Copy**

## **Document made available under the Patent Cooperation Treaty (PCT)**

International application number: PCT/US04/017649

International filing date: 04 June 2004 (04.06.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/514,768  
Filing date: 27 October 2003 (27.10.2003)

Date of receipt at the International Bureau: 19 August 2004 (19.08.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1211247

UNITED STATES OF AMERICA

AND ANY ORGANIZATION THEREIN, GOVERNMENT OR PRIVATE.

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

August 12, 2004


THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.

APPLICATION NUMBER: 60/514,768

FILING DATE: *October 27, 2003*

RELATED PCT APPLICATION NUMBER: PCT/US04/17649

Certified by



Jon W Dudas

Acting Under Secretary of Commerce  
for Intellectual Property  
and Acting Director of the U.S.  
Patent and Trademark Office

Approved for use through 10/31/2002. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EV322656729US

U.S. PTO  
60/514768  
2254  
102703

### INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Feiling	Wang	Medford, Massachusetts

Additional inventors are being named on the \_\_\_\_\_ separately numbered sheets attached hereto

### TITLE OF THE INVENTION (500 characters max)

### COHERENCE-GATED OPTICAL GLUCOSE MONITOR

Direct all correspondence to:

### CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number	<input type="text"/>	→	<input type="checkbox"/> Place Customer Number Bar Code Label here
OR	Type Customer Number here		

<input checked="" type="checkbox"/> Firm or Individual Name	Mills & Onello LLP				
Address	Eleven Beacon Street				
Address	Suite 605				
City	Boston	State	MA	ZIP	02108
Country	United States	Telephone	(617) 994-4900	Fax	(617) 742-7774

### ENCLOSED APPLICATION PARTS (check all that apply)

<input checked="" type="checkbox"/> Specification Number of Pages	<input type="text" value="6"/>	<input type="checkbox"/> CD(s), Number	<input type="text"/>
<input type="checkbox"/> Drawing(s) Number of Sheets	<input type="text"/>	<input type="checkbox"/> Other (specify)	<input type="text"/>
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76			

### METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.	<input type="checkbox"/> FILING FEE AMOUNT (\$)
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees	<input type="text" value="160.00"/>
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:	<input type="text" value="50-1798"/>
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.	

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_

Respectfully submitted

SIGNATURE

TYPED or PRINTED NAME Steven M. Mills

TELEPHONE (617) 994-4901

Date 10/27/2003

REGISTRATION NO.  
(if appropriate)  
Docket Number:

36,610

TOM-0002PR

### USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office; U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

PATENT  
Attorney Docket No.: TOM-0002PR  
Customer No.: 29344

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Feiling Wang  
Filing Date: Herewith  
Title: COHERENCE-GATED OPTICAL GLUCOSE MONITOR

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10

"Express Mail" Mailing Label Number EV322656729US I hereby certify that this paper and other papers enclosed herewith or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to Mail Stop Provisional Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10-27-03

Date



Vanessa Marakas

Mail Stop Provisional Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed herewith for filing in the above-identified provisional patent application please find the following listed items:

1. Provisional Application Cover Sheet;
2. Provisional Patent Application including six (6) pages of specification;
3. Check in the amount of \$160.00 to cover application filing fee; and
4. Return Postcard.

In connection with the foregoing matter, please charge any additional fees which may be due, or credit any overpayment, to Deposit Account Number 50-1798. A duplicate copy of this letter is provided for this purpose.

Respectfully submitted,

  
Steven M. Mills

Registration Number 36,610  
Attorney for Applicant

Date: October 27, 2003  
Mills & Onello LLP  
Eleven Beacon Street, Suite 605  
Boston, MA 02108  
Telephone: (617) 994-4900  
Facsimile: (617) 742-7774

**Invention Disclosure: Coherence-Gated Optical Glucose Monitor**

**Inventor:** Feiling Wang

**Date:** October 20, 2003

**Affiliation:**

Tomophase Corporation  
38 Montvale Avenue, Suite 260  
Stoneham, MA 02180

**Home address:**

54 Forest Street, Unit 322  
Medford, MA 02155


**1. Description of Invention**

The invention is concerned with a method and apparatus to monitor the glucose level of diabetes patients with an optical and noninvasive technique.

Presently, dependable glucose monitors rely on taking blood samples from diabetes patients. Repeated pricking of skin can cause considerable discomfort for patients. It is therefore desirable to monitor the glucose level in a noninvasive manner.


It is well known that glucose in blood possesses "signature" optical absorption peaks in a near-infrared (NIR) wavelength range. It is also appreciated the main obstacle in noninvasive monitoring of glucose is due to the fact that a probing light beam interacts, in its path, with various types of tissues and substances which possess overlapping absorption bands. Extracting the signature glucose peaks amongst all other peaks has proven difficult.

This invention addresses the difficulty through "coherence gating", a technique by which one can acquire the absorbance spectrum of a particular and designated layer beneath the skin surface. For glucose monitoring, the designated layer is preferably the dermis layer where glucose is concentrated in a network of blood vessels and interstitial fluid, as shown in Fig. 1.



**Figure. 1**

The coherence gating is accomplished by the use of a low-coherence interferometer. There are many possible optical configurations for the low-coherence interferometer. Figure 2 shows one design based on a Michelson interferometer.



In the design shown, the light source emits broadband NIR radiation covering the characteristic absorption peaks of the glucose. The polarizing beam splitter, PBS1, splits the light into two parts which are mutually orthogonal in polarization to one another. While one part is directed towards a mirror, R, to be the reference beam the other is incident on the skin of a patient. The two polarization rotators, PR1 and PR2, render the polarization states of the two reflected beams orthogonal to their original states so that they are recombined at PBS1 and propagate towards the detection subsystem. The tunable bandpass filter, TBF, allows a variable portion of the spectrum in the reflected beams to reach the detectors. The movable mirror can be positioned so that its distance from PBS1 matches that between PBS1 and a desirable interface in the skin. Due to the low coherence, only the reflected (or backscattered) light originated in the vicinity of the matching interface can form interference fringes with the reference beam. Temporal interference fringes (intensity oscillation) can be generated with the help of the phase modulator.

For the simplicity of description let us assume that the wavelength dependent attenuation coefficient of the epidermis layer is  $\mu_e(\lambda)$  and that of the dermis  $\mu_d(\lambda)$ . These attenuation coefficients are closely related to the absorbance spectra of the layers. Let us further assume that the tissue in the vicinity of interface I (II) possesses an effective reflection coefficient  $r_I$  ( $r_{II}$ ). Interface I separates the epidermis and the dermis; and interface II separates the dermis and the subcutaneous tissues.

Let us first position the mirror at  $I'$  to approximately match interface I. The reflected light originated around the interface creates an interfering echo whose amplitude is given by

$$A_I(\lambda) = r_I e^{-2\mu_e(\lambda)z_e} \quad (1)$$

where  $z_e$  is the thickness of the epidermis. Now if we relocate the mirror to  $II'$  to approximately match interface  $II$ ,  $r_{II}$  gives rise to a different interfering echo whose amplitude is given by

$$A_{II}(\lambda) = r_{II} e^{-2\mu_e(\lambda)z_e - 2\mu_d(\lambda)z_d} \quad (2)$$

where  $z_d$  is the thickness of the dermis. With the use of the phase modulator these echoes interfere with the reference and produce proportional intensity oscillations measurable by the detector. To acquire the absorption characteristics of the dermis one can divide Eq. (2) by Eq. (1) to obtain

$$\frac{A_{II}(\lambda)}{A_I(\lambda)} = \frac{r_{II}}{r_I} e^{-2\mu_d(\lambda)z_d} \quad (3)$$

We have thus acquired, with Eq. (3), the absorption characteristics of the dermis layer only. The absorbance spectrum of the dermis is closely represented by coefficient  $\mu_d(\lambda)$  because of the weak wavelength dependence of scattering.

It is known that the superficial epidermis layer, owing to its pigment content, is the dominant source of NIR absorption. Because of the absence of blood, however, the epidermis yields no useful information for glucose monitoring. With the invented method we can acquire solely the absorbance spectrum of the dermis layer by rejecting the absorptions of the epidermis and the subcutaneous tissues. An additional advantage is from the fact that dermis exhibits less temperature variation compared to the epidermis. It is known that surface temperature variation causes shifts of water absorption, hampering glucose monitoring.

In the above discussion it has been assumed that the pass band of the tunable filter is broad enough to facilitate the coherence gating and at the meantime narrow enough to resolve the characteristic glucose peaks. Let us now examine whether the assumption is reasonable and practical.

It is known that some predominant glucose absorption peaks reside in a wavelength range between 1 and 2.5 microns, as shown in Fig. 3. The width of these peaks are approximately 150 nm. To resolve the peaks let us choose the bandwidth of the tunable bandpass filter to be around 30 nm. The depth resolution (gating ability) is determined by the following equation:

$$\frac{2 \ln(2) \lambda_0^2}{\pi \Delta \lambda} = 60 \mu m \quad (4)$$

The thickness of the epidermis is typically 0.1 mm and that of the dermis typically 1 mm. The above analysis (Eq. (4)) indicates that the coherence gating technique described above can comfortably resolve both the absorption peaks and the skin layers. It is therefore feasible to isolate the absorbance spectrum of the dermis layer from the epidermis and the subcutaneous tissues.




Figure. 3

To acquire the absorbance spectrum of the dermis layer one may operate the apparatus shown in Fig. 2 in this sequence: 1) locate the mirror at I' so that its distance matches the interface separating the epidermis and the dermis layers (position I); 2) scan the tunable bandpass filter across the span of the glucose signature peaks while recording the amplitude of the light intensity oscillation so that Eq. (1) is acquired; 3) relocate the mirror to II' so that its distance matches the interface separating the dermis and the subcutaneous tissues (position II); 4) repeat the process of step 2) so that Eq. (2) is also acquired. The absorbance spectrum of the dermis can be found by using Eq. (3). It should be appreciated that additional signal processing is necessary in order to determine the glucose concentration from the measured absorbance spectrum of the dermis.

The tunable bandpass filter can be one of the following devices: an electro-optically tunable filter, a rotatable fixed bandpass filter or a rotatable grating. The polarization rotators in the design can be quarter-wave plates or Faraday rotators. The movable mirror can be replaced by a non-mechanical device such as a liquid-crystal cell or a combination of polarization rotators and birefringent crystals.

It should be appreciated that the use of the two detectors along with the second polarizing beam splitter, PBS2, facilitates a differential detection scheme for high signal to noise ratio. It is obvious that one can simplify the design to include a single detector with a linear polarizer.

## 2. Embodiment with Non-polarized Beams

It is not necessary to arrange the polarization of the light beams in the way described above. An alternative optical configuration for the same purpose is shown in Fig. 4. In this design the polarizing beam splitter is replaced by a non-polarizing beam splitter. The polarization states of the light beams can be arbitrary. With this design, however, only half of the light energy reaches the detector.




Figure 4

### 3. Embodiment with Detector Array

The absorbance spectrum can also be resolved by a dispersive device and a detector array instead of the tunable bandpass filter. In the design shown in Fig. 5, a reflective grating is coupled with an array of detectors. With this design the speed of data acquisition can be substantially increased through parallel processing. This design can also be reconfigured to accommodate polarized light beams, similar to what shown in Fig. 2.




Figure 5

### 4. Embodiment without Spectrum Analyzer

The absorbance spectrum of the substances may also be acquired by means of post-detection signal analysis without the help of a tunable bandpass filter or a grating with detector array. This simplifies the design shown in Fig. 2 to that in Fig. 6. The same simplification can be applied to the non-polarizing version shown in Fig. 4.

Without a spectrum analyzer the absorbance spectrum of the tissues may be directly calculated from the intensity oscillation created by the interfering beams of the whole spectra. Certain mathematical transformations, such as a suitable wavelets transformation, may be adopted for such task.




Figure 6

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**